Format

Send to

Choose Destination
See comment in PubMed Commons below
Aktuelle Urol. 2010 Jan;41 Suppl 1:S57-60. doi: 10.1055/s-0030-1247237. Epub 2010 Jan 21.

Progress in the management of advanced renal cell carcinoma (RCC).

Author information

  • 1Department of Urology, Academic Hospital Duisburg, Duisburg, Germany. tqttong@gmail.com

Abstract

A more profound understanding in the pathophysiological mechanism of renal cell cancer has led to a shift in the treatment approach. Traditionally, cytokines were the frontline drugs, but recently this has transitioned to drugs interacting vascular endothelial growth factor (VEGF) related pathway. Sorafenib, sunitinib, bevacizumab, temsirolimus and everolimus have demonstrated clinical improvements in randomized trials. The purpose of this review is to summarise the current management of advanced RCC.

PMID:
20094957
DOI:
10.1055/s-0030-1247237
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Georg Thieme Verlag Stuttgart, New York
    Loading ...
    Support Center